📅 PUBMED DAILY TRIAGE — 2026-05-22

Window: 2026-05-21T09:00:00Z → 2026-05-22T09:00:00Z (CRDT) Topics scanned: 10 | Candidates evaluated: ~93 | Articles reviewed in depth: ~55 High priority: 5 | Standard: 15 | Low/archive: ~38 | Unsolicited finds: 2 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

CBC-Based Diagnostics & ML in Hematology ⭐ BREAKOUT RUN

TR-2026-05-22-001 / PMID 42166702 · ML Model Predicts Monoclonal Gammopathy Using Routine Laboratory Values · 8/10 · 🔴 EARLY_CANCER_DETECTION

JCO Clin Cancer Inform | Movassagh et al. | Sonic Healthcare USA XGBoost model predicts M-protein (MGUS/myeloma precursor) with AUC 0.84 from routine CBC+metabolic panel in 232,813-patient retrospective cohort; top features: lymphocyte trajectory, RBC, RBC distribution width. First broadly validated CBC-only ML model for monoclonal gammopathy detection. First HIGH result for this topic after 8 consecutive zero-HIGH runs.

Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)

TR-2026-05-22-002 / PMID 42168180 · CAcTUS trial: ctDNA-guided treatment switching targeted→immune therapy in BRAF mutant melanoma · 8/10 · 🟠 NOVEL_TREATMENT

Nat Commun | Lee/Rothwell/Lorigan et al. | University of Manchester / Christie NHS Trust Randomized phase II feasibility trial; 100% of ctDNA-guided switch decisions delivered within 7 days (primary endpoint met); longitudinal ctDNA dynamics provide early ICI benefit signal and evidence for TT rechallenge after ICI progression. First randomized evidence for ctDNA-guided treatment sequencing in BRAF melanoma.

Hematologic Malignancies / Novel Therapeutics

TR-2026-05-22-003 / PMID 42167809 · Human CART22.19 therapy in refractory pediatric B-ALL: named-patient cohort · 7/10 · 🟠 NOVEL_TREATMENT

J Immunother Cancer | Mast/Lang/Handgretinger et al. | University Hospital Tübingen Dual CD22+CD19-targeting CAR-T addresses CD19 antigen escape (primary resistance mechanism in B-ALL); named-patient compassionate-use cohort in refractory disease; high-impact journal. NOVEL_TREATMENT flag → HIGH.

Novel Therapeutics — Expanded Paradigm

TR-2026-05-22-004 / PMID 42168367 · Resetting autoimmune disease with CAR cell therapies · 7/10 · 🟠 NOVEL_TREATMENT (unsolicited find)

Nat Med | Schett G, Xu H | FAU Erlangen / Naval Medical University Shanghai Comprehensive Nat Med review on CAR-T (CD19/BCMA) as 'immune reset' in autoimmune diseases; covers autologous vs. allogeneic approaches; growing evidence base with deep B cell depletion; expands CAR-T paradigm beyond oncology.

Precision Oncology / PDAC

TR-2026-05-22-005 / PMID 42168502 · Olverembatinib + gemcitabine in PDAC · 6/10 · 🟠 NOVEL_TREATMENT

NPJ Precis Oncol | Xia/Guan/Yang et al. | Sun Yat-Sen University Cancer Center Novel BCR-ABL TKI (approved for CML/ALL) repurposed in PDAC; SRC/AKT/cMYC and JAK1-STAT1 synergy with gemcitabine; preliminary clinical efficacy in multi-line refractory PDAC. NOVEL_TREATMENT flag → HIGH despite mixed preclinical/clinical design.

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies

• TR-006 / PMID 42168078 · HCT with PTCy in AML/MDS >70 years (CIBMTR, n=431) · 7/10 · Treatment Innovation — Higher NRM but comparable relapse/GVHD vs younger; supports individualized over age-based exclusion
• TR-015 / PMID 42167607 · ML for CLABSI risk in pediatric leukemia using CBC features (n=407, 91.2% accuracy) · 6/10 · Diagnostics

CBC-Based Diagnostics & ML

• TR-016 / PMID 42167067 · Immature platelet fraction for thrombocytopenia classification (n=444, AUC 0.86) · 6/10 · Diagnostics — Near-term implementable cut-off (IPF 8.3%)
• TR-017 / PMID 42165722 · ML predicts IDA from CBC alone (RF, ~95% sens/spec, NHANES + Indian validation) · 6/10 · Diagnostics — Low-resource applicable

Early Cancer Detection

• TR-009 / PMID 42168657 · CSF ctDNA (600-gene NGS) enables glioma reclassification; 60% mutation detection; 3 patients reclassified per WHO 2021 (n=43) · 7/10 · Diagnostics
• TR-018 / PMID 42168331 · AI+ML in liquid biopsy for early PDAC: scoping review (18 studies) · 5/10 · Early Detection

AI/ML Diagnostics & Imaging

• TR-010 / PMID 42168606 · YOLOv5 Endosmart AI for gastric lesion detection (n=34,979; AUC 0.965; external validation vs endoscopists) · 6/10 · Diagnostics

Precision Oncology

• TR-011 / PMID 42168613 · Y chromosome LOY in male cancers (Nat Rev Cancer): LOY as cancer risk biomarker + immunotherapy response predictor · 6/10 · Genomics/Precision Medicine

Novel Therapeutics

• TR-012 / PMID 42168759 · CONPELAN (Pembrolizumab post-CRT in NPC, randomized phase II, n=53): negative in unselected patients; TIL density biomarker signal · 6/10 · Treatment Innovation

Cardiovascular-Metabolic

• TR-007 / PMID 42168641 · GLP-1RA/tirzepatide discontinuation: causes and cardiometabolic consequences (Nat Rev Endocrinol) · 7/10 · Public Health — Clinically urgent problem; stop-start cycle cardiovascular risk
• TR-008 / PMID 42168767 · GLP-1R PET/CT ([68Ga]exendin-4) for insulinoma: 72% detection after negative conventional imaging (n=101, dual-center) · 7/10 · Diagnostics — Near-term implementable

Rare Diseases

• TR-013 / PMID 42168009 · PLS French National Diagnostic and Care Protocol (FILSLAN): first national guideline for rare MND · 6/10 · Diagnostics / Rare disease
• TR-014 / PMID 42166534 · HAE-C1INH in elderly (ITACA registry, n=647): persistent disease + treatment gap (androgens still 22.2%) · 6/10 · Underserved population

Aging & Longevity

• TR-019 / PMID 42168785 · Arteriolosclerosis MRI biomarker (ARTS) links cardiometabolic risk to ATN(V) Alzheimer's biomarkers (n=238) · 5/10 · Diagnostics / Prevention

💡 UNSOLICITED FINDS

• TR-004 / PMID 42168367 · CAR-T for autoimmune diseases (Nat Med review) — watchlist covers CAR-T in oncology; autoimmune application is major adjacent paradigm shift. HIGH priority via NOVEL_TREATMENT flag.
• TR-020 / PMID 42168749 · Circulating hybrid cells (CHCs) as novel liquid biopsy (Adv Exp Med Biol review) — tumor-immune fusion products for early detection, distinct from ctDNA. STANDARD.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 3 | Treatment Innovation: 7 | Diagnostics: 8 | Genomics/Precision Medicine: 2 | Public Health: 2 | Drug Development: 1 | Review: 3

By evidence maturity:

• Exploratory: 10 | Validated: 9 | Potentially Practice-Changing: 1

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed 20 | preprint 0

Topics with zero 8+ articles this run: AI/ML diagnostics, Cardiovascular-metabolic, Aging/longevity, Rare diseases

🔧 RUN NOTES

CBC/ML Topic — Breakout: The reformulated query (v2) using specific hematology instrument terms + broader ML terms yielded 4 clean results (vs. prior noise-heavy queries), producing the first HIGH result in 8 consecutive runs for this topic (PMID 42166702, JCO Clin Cancer Inform). Prior query relied on broader field terms that returned low-signal articles. Recommend maintaining reformulated v2 query.

CAcTUS Trial Significance: PMID 42168180 is likely a clinically significant finding — a ctDNA-guided treatment sequencing paradigm in melanoma published in Nat Commun as a full Phase II report. The primary feasibility endpoints (100% timely results, 100% ctDNA response) position this for future phase III.

CAR-T Expansion Beyond Oncology: PMID 42168367 (Nat Med) signals the mainstreaming of CAR-T in autoimmune disease, a paradigm shift with major health system implications. Pipeline should flag for separate autoimmune-focused sub-track if warranted.

No window expansion triggered: 20 relevant records found (>5 threshold satisfied).

Duplicate check: All 20 PMIDs confirmed absent from prior emitted fingerprints.

Rolling 7-day topic signal tracker (inferred from state):

• CBC/ML HIGH count over 8 days: 0+0+0+0+0+0+0+1 = 1 (breakthrough today)
• AI/ML diagnostics: consistent 0 HIGH across multiple runs — consider query refine next week